AstraZeneca (NASDAQ:AZN) used its presentation at the J.P. Morgan Healthcare Conference to highlight strong 2025 performance, a growing late-stage pipeline, and management’s confidence in sustaining ...
AstraZeneca is relying on several upcoming products to help hit its target of $80 billion in revenue by 2030, including drugs ...
AstraZeneca has agreed to buy Boston-based Modella AI, the companies said on Tuesday, as the drug industry increases its use ...
As President Donald Trump’s tariff policies loom, global pharmaceutical giant AstraZeneca will invest $50 billion to boost its American manufacturing and R&D infrastructure. Chief among the company’s ...
CAMBRIDGE, England--(BUSINESS WIRE)--AstraZeneca today announces $3.5 billion of capital investment in the United States focused on expanding the Company’s research and manufacturing footprint by the ...
Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter and ...
As Nxera Pharma proceeds into the “next era” implied by its name—following a rebrand from Sosei Group last year—the Japanese drugmaker is adding a new executive to help guide its growth plans. Kiyoshi ...
AstraZeneca has named Rick R. Suarez as Senior Vice President, U.S. President and Head of the U.S. Biopharmaceuticals ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback